A phase 1 study of REGN6569, a GITR mAb, in combination with cemiplimab in patients (pts) with advanced solid tumor malignancies: Initial dose-escalation results

被引：0
|
作者：
Lakhani, Nehal J.
Hamid, Omid
Brana, Irene
Lostes-Bardaji, M. Julia
Gajate, Pablo
Lopez-Criado, Maria Pilar
Swiecicki, Paul
de Miguel, Maria J.
Gil-Martin, Marta
Moreno, Victor
Muller, Aixa Elena Soyano
Ortiz, Ana Gonzalez
Sun, Dylan
Modi, Dimple
Zheng, Wenjun
Jankovic, Vladimir
Salvati, Mark
Fury, Matthew G.
Cristea, Mihaela C.
机构：
[1] START Midwest, Grand Rapids, MI USA
[2] Angeles Clin & Res Inst, Los Angeles, CA USA
[3] Vall dHebron Univ Hosp, Barcelona, Spain
[4] Inst Oncol, Barcelona, Spain
[5] Inst Oncol VHIO, Barcelona, Spain
[6] Ramon & Cajal Univ Hosp, Madrid, Spain
[7] Univ Texas MD Anderson Canc Ctr, Madrid, Spain
[8] Univ Michigan, Ann Arbor, MI 48109 USA
[9] START Madrid CIOCC, Madrid, Spain
[10] Inst Catala Oncol IDIBELL, Barcelona, Spain
[11] Hosp Fdn Jimenez Diaz, START Madrid, Madrid, Spain
[12] H Lee Moffitt Canc Ctr & Res Inst, Tampa, FL USA
[13] Regeneron Pharmaceut Inc, Tarrytown, NY USA
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2024年 / 42卷 / 16期
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
2650
引用
收藏
页数：1
相关论文
共 50 条
  • [1] A PHASE 1/2 STUDY OF REGN7075 (EGFRXCD28 COSTIMULATORY BISPECIFIC ANTIBODY) IN COMBINATION WITH CEMIPLIMAB (ANTI-PD-1) IN PATIENTS WITH ADVANCED SOLID TUMORS: INITIAL DOSE-ESCALATION RESULTS
    Johnson, Melissa
    Lakhani, Nehal
    Girda, Eugenia
    Olszanski, Anthony
    Fong, Lawrence
    Han, Hyunsil
    Casey, Kerry
    Li, Siyu
    Visich, Jennifer
    Skokos, Dmitris
    Seebach, Frank
    Lowy, Israel
    Fury, Matthew
    Mathias, Melissa
    Segal, Neil
    JOURNAL FOR IMMUNOTHERAPY OF CANCER, 2022, 10 : A767 - A768
  • [2] Phase 1 Dose-Escalation Study of TAK-659, an Investigational SYK Inhibitor, in Patients (Pts) with Advanced Solid Tumor or Lymphoma Malignancies
    Petrich, Adam M.
    Gordon, Leo I.
    Infante, Jeffrey R.
    Madan, Sumit
    Giles, Francis J.
    Nimeiri, Halla S.
    Kaplan, Jason B.
    Stumpo, Kate
    Zhang, Bin
    Faucette, Stephanie
    Shou, Yaping
    Shih, Kent C.
    BLOOD, 2015, 126 (23)
  • [3] A phase 1/2 study of REGN7075 in combination with cemiplimab (cemi) in patients (pts) with advanced solid tumors: Efficacy and safety results
    Segal, Neil Howard
    Girda, Eugenia
    Sohal, Davendra
    Lakhani, Nehal J.
    Olszanski, Anthony J.
    Fong, Lawrence
    Kinnaman, Michael David
    Han, Hyunsil
    Skokos, Dimitris
    Casey, Kerry A.
    Wang, JuAn
    Wang, Bei
    Hao, Yi
    Li, Siyu
    Ganguly, Samit
    Lowy, Israel
    Seebach, Frank A.
    Mathias, Melissa Divya
    Johnson, Melissa Lynne
    JOURNAL OF CLINICAL ONCOLOGY, 2024, 42 (16)
  • [4] Phase I Dose-Escalation Study of Onartuzumab as a Single Agent and in Combination with Bevacizumab in Patients with Advanced Solid Malignancies
    Salgia, Ravi
    Patel, Premal
    Bothos, John
    Yu, Wei
    Eppler, Steve
    Hegde, Priti
    Bai, Shuang
    Kaur, Surinder
    Nijem, Ihsan
    Catenacci, Daniel V. T.
    Peterson, Amy
    Ratain, Mark J.
    Polite, Blase
    Mehnert, Janice M.
    Moss, Rebecca A.
    CLINICAL CANCER RESEARCH, 2014, 20 (06) : 1666 - 1675
  • [5] Sunitinib combined with pemetrexed and carboplatin in patients with advanced solid malignancies—results of a phase I dose-escalation study
    Normand Blais
    D. Ross Camidge
    Derek J. Jonker
    Denis Soulières
    Scott A. Laurie
    Sami G. Diab
    Ana Ruiz-Garcia
    Aron Thall
    Ke Zhang
    Richard C. Chao
    Laura Q. Chow
    Investigational New Drugs, 2013, 31 : 1487 - 1498
  • [6] EZN-2208, a novel anticancer agent, in patients (pts) with advanced malignancies: A phase 1 dose-escalation study
    Patnaik, Amita
    Papadopoulos, Kyriakos P.
    Beeram, Muralidhar
    Kee, Debbie
    Tolcher, Anthony W.
    Schaaf, Larry J.
    Tahiri, Sanaa
    Bekaii-Saab, Tanios
    Buchbinder, Aby
    MOLECULAR CANCER THERAPEUTICS, 2009, 8 (12)
  • [7] Sunitinib (SU) in combination with pemetrexed (P) in patients (pts) with advanced solid malignancies: A phase I dose escalation study
    Chow, L. Q.
    Jonker, D. J.
    Laurie, S. A.
    Call, J. A.
    Diab, S. G.
    Goss, G.
    McWilliam, M.
    Wang, E.
    Chao, R.
    Eckhardt, S. G.
    Camidge, D. R.
    JOURNAL OF CLINICAL ONCOLOGY, 2008, 26 (15)
  • [8] A PHASE I DOSE ESCALATION STUDY OF SUNITINIB (SU) IN COMBINATION WITH PEMETREXED (PEM) IN PATIENTS (PTS) WITH ADVANCED SOLID MALIGNANCIES
    Chow, L. Q. M.
    Jonker, D. J.
    Laurie, S. A.
    Call, J. A.
    Diab, S. G.
    McWilliam, M.
    Wang, E.
    Chao, R.
    Eckhardt, S. G.
    Camidge, D. R.
    ANNALS OF ONCOLOGY, 2008, 19 : 159 - 159
  • [9] Phase I dose-escalation study of cabazitaxel administered in combination with gemcitabine in patients with metastatic or unresectable advanced solid malignancies
    Rixe, Olivier
    Puzanov, Igor
    LoRusso, Patricia M.
    Cohen, Roger B.
    Morris, John C.
    Olowokure, Olugbenga O.
    Yin, Jian Y.
    Doroumian, Severine
    Shen, Liji
    Olszanski, Anthony J.
    ANTI-CANCER DRUGS, 2015, 26 (07) : 785 - 792
  • [10] BEZ235 in combination with everolimus for advanced solid malignancies: Preliminary results of a phase Ib dose-escalation study.
    Salkeni, Mohamad Adham
    Rixe, Olivier
    Karim, Nagla Abdel
    Ogara, Sue
    Feiler, Monica
    Moorthy, Ganesh
    Mercer, Carol A.
    Thomas, Hala
    Desai, Pankaj B.
    Fathallah, Hassana
    Kozma, Sara
    Thomas, George
    Morris, John Charles
    JOURNAL OF CLINICAL ONCOLOGY, 2013, 31 (15)
12345